To leverage TRIPS effectively for improving cancer care, countries can utilize its flexibilities, such as compulsory licensing, to improve access to affordable treatments. Additionally, fostering collaborations in healthcare between developed and developing countries, encouraging technology transfer, and supporting local pharmaceutical industries can enhance the availability of cancer drugs. Policymakers and stakeholders must work together to ensure that the benefits of innovation reach all patients, regardless of economic status.
